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Abstract 
The advent of the easily programmable and efficient CRISPR/Cas9 nuclease system has 
revolutionized genetic engineering. While conventional gene knockout experiments using 
CRISPR/Cas9 are very valuable, these are not well suited to study stage-specific gene function in 
dynamic situations such as development or disease. Here we describe a CRISPR/Cas9-based 
OPTimized inducible gene KnockOut method (OPTiKO) for conditional loss-of-function studies 
in human cells. This approach relies on an improved tetracycline-inducible system for 
conditional expression of single guide RNAs (sgRNAs) that drive Cas9 activity. In order to 
ensure homogeneous and stable expression, the necessary transgenes are expressed following 
 2 
rapid and efficient single-step genetic engineering of the AAVS1 genomic safe harbor. When 
implemented in human pluripotent stem cells (hPSCs), the approach can be then efficiently 
applied to virtually any hPSC-derived human cell type at various stages of development or 
disease. 
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1 Introduction 
 
The genomics revolution brought the key challenge of functionally annotating an ever-
growing list of both coding and non-coding genetic variants linked to human development, 
physiology, and disease [1, 2]. As a result, there is a high demand for simple, scalable, rapid, 
and robust platforms for functional genetic analyses in multiple human cell types, including 
populations that are transitory during development, rare, or inaccessible. Loss-of-function 
experiments in human pluripotent stem cells (hPSCs: human embryonic stem cells, hESCs, 
or human induced pluripotent stem cells, hiPSCs) provide a unique opportunity to address 
this major challenge, as hPSCs can provide an unlimited source of virtually any somatic cell 
type of clinical interest [3–5]. However, the study of gene function at specific stages of 
differentiation requires efficient methods to conditionally manipulate gene expression in both 
hPSCs and hPSC-derived cells. 
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In recent years, our ability to interrogate gene function has been revolutionized by the rise of 
gene editing methods based on CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats) and associated Cas genes, particularly CRISPR/Cas9 [6–8]. The most popular 
version of this approach is based on a modified prokaryotic type II CRISPR/Cas9 system in 
which the DNA endonuclease Cas9 protein is selectively targeted to a genomic region by a 
single guide RNA (sgRNA). In such sgRNA, an approximately 20 base pairs (bp) sequence-
specific “target” region (CRISPR RNA, or crRNA) is joined to an invariable “scaffold” 
sequence (trans-activating crRNA, or tracrRNA). The target region is designed to be perfectly 
complementary to a specific genomic region that is immediately followed by the essential 
protospacer adjacent motif (PAM) 5’-NGG-3’site. Upon binding, Cas9 cleaves the DNA to 
generate double-strand breaks that are predominantly repaired by error-prone non-
homologous end joining (NHEJ), resulting in random small insertions of deletions (indels) 
that can generate loss-of-function alleles [9, 10].  
 
CRISPR/Cas9-based methods for inducible loss-of-function in hPSCs have been reported 
[11–13]. However, these approaches are either significantly complex and time-consuming, as 
they involve multiple genome editing steps that must be tailored to each individual gene [12], 
or are not widely applicable in hPSC-derived cells, as they rely on inducible promoters that 
are not stably and homogeneously expressed following hPSC differentiation [11, 13–16]. We 
recently developed an alternative approach that bypasses these limitations by allowing 
generation of inducible knockout hPSCs with a single gene editing step introducing 
transgenes that are stably expressed in hPSC-derived cell types [16]. This method, which we 
named OPTiKO (for OPTimized inducible gene KnockOut), allows streamlined, highly-
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efficient, homogeneous, and rapid induction of loss-of-function mutations in both hPSCs and 
hPSC-derived lineages [16]. Recently, this has also been used as an in vitro platform for the 
screening of efficient sgRNAs to be used for CRISPR/Cas9 gene editing in human embryos 
[17].  
 
OPTiKO combines the CRISPR/Cas9 technology with an optimized tetracycline-
derepressible (TET-OFF) system: hPSCs are genetically engineered to carry a constitutively 
expressed Cas9 protein that is only activated following tetracycline-induced expression of the 
sgRNA (Fig. 1). To its core, this relies on an H1 RNA polymerase III promoter that was 
modified to include a tet operator (tetO2) sequence after the TATA box [18] (H1-TO; Fig. 2). 
The tetO2 is strongly bound by a tetracycline-sensitive Repressor protein that was codon-
optimized to maximise its expression in human cells (OPTtetR) [16]. While this prevents 
sgRNA expression in normal culture conditions, as a result of tetracycline treatment the 
tetracycline-bound OPTtetR undergoes a conformational change that relieves its binding to 
the H1-TO promoter, which is therefore derepressed. To ensure strong, homogeneous, and 
stable expression even after hPSC differentiation, all of the necessary transgenes are 
integrated into the well-characterized AAVS1 genomic safe harbor [19–22]. This is achieved 
by means of single-step zinc finger nuclease (ZFN)-facilitated gene editing [23], which was 
optimized to ensure on-target recombination efficiency greater than 90% [16, 20]. OPTiKO 
relies on targeting each allele of the AAVS1 locus with one of two targeting plasmids: the first 
(pAAV-Neo_CAG-Cas9) carries the constitutively expressed Streptococcus Pyogenes Cas9 
transgene, while the second (pAAV-Puro_siKO) carries the inducible sgRNA cassette and 
the constitutive OPTtetR (Fig. 2a and 3a). As these vectors also carry two distinct gene trap-
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based drug resistance genes, respectively for neomycin and puromycin, hPSCs that express 
both transgenes are selected by means of dual drug selection. When the resulting OPTiKO 
hPSCs carry an inducible sgRNA designed to generate NHEJ-mediated loss-of-function 
mutations, gene knockout can be induced at any stage of hPSC differentiation by addition of 
tetracycline (Fig. 1). 
 
[Fig. 1 near here] 
 
The following protocol describes all of the procedures required for the generation and 
validation of OPTiKO hPSCs. First, the sgRNA specific to the gene of interest is designed 
and cloned as a double-strand oligonucleotide into pAAV-Puro_siKO (Subheading 3.1; Fig. 
2). Then, hPSCs are nucleofected with the AAVS1 ZFN plasmids and targeting vectors, and 
dual-gene targeted lines are selected using puromycin and neomycin (Subheading 3.2; Fig.3). 
Clonal hPSC lines are isolated and characterized by genomic PCR to identify correctly 
targeted clones (Subheading 3.3; Fig.4). Finally, the resulting OPTiKO hPSCs are validated 
to induce efficient gene knockout by confirming loss of the protein product upon tetracycline 
treatment (Subheading 3.4; Fig.5). The whole procedure can be completed in 4-9 weeks 
depending on the experimental design and expertise of the investigator, and allows generation 
of OPTiKO hPSCs with >90% efficiency. The protocol shares similarities with a related 
method to generate inducible knockdown hPSCs, which can serve as additional reference [16, 
24]. 
 
2 Materials 
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Prepare all solutions using analytical grade chemicals, and DNase- and RNase-free ultrapure 
deionized water (dH2O). Store all reagents at room temperature, unless indicated otherwise 
below or in the supplier’s instructions. Hazardous reagents must be handled with care while 
wearing appropriate personal protective equipment and in accordance with local safety 
regulations. Waste materials are to be disposed according to the relevant regulations. Standard 
equipment used in molecular biology and cell culture research is required for this protocol (e.g., 
micropipettes, a tabletop microcentifuge, and a serological pipette controller). Certain materials 
are required at multiple stages of the protocol. 
 
2.1 Molecular cloning 
1. pAAV-Puro_siKO plasmid (available from the corresponding authors). 
2. Oligonucleotides for sgRNA target (custom, see Subheading 3.1 step 2). 
3. AarI restriction enzyme (2 U/µL; ThermoFisher Scientific Cat. No. ER1581). 
4. DNA loading dye (6X): 60% glycerol; 10 mM Tris-HCl (pH 7.6); 60 mM EDTA; 0.03% 
bromophenol blue; 0.03% xylene cyanol. 
5. TAE electrophoresis buffer (50X): 2 M Tris base; 1 M acetic acid; 50 mM EDTA 
disodium salt. 
6. Agarose I, molecular biology grade 
7. Ethidium bromide: 10 mg/ml stock solution in dH2O. 
8. Agarose gel in TAE: dissolve the required amount of agarose powder into 100 mL of 1X 
TAE in a glass bottle. Place a cap on the bottle but leave loose. Incubate at room 
temperature for 15’ to pre-dissolve. Microwave for about 1-2’ or until all of the powder is 
fully dissolved, but do not let the solution boil. Allow the solution to cool at room 
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temperature for 5-10’ (the temperature of the solution should not go below 65 °C to 
prevent premature gelling), and add ethidium bromide to a final concentration of 0.5 
µg/mL. After mixing pour the solution into a gel casting tray equipped with the 
appropriate combs and let the gel set for 30 minutes before use. 
9. DNA electrophoresis apparatus. 
10. DNA molecular weight ladder. 
11. UV transilluminator. 
12. QIAEX II Gel Extraction Kit (150 extractions; QIAGEN Cat. No. 20021). 
13. Oligo annealing buffer (10X): 100 mM Tris-HCl (pH 8); 10 mM EDTA; 1 M NaCl. 
14. Thermocycler with heated lid. 
15. T4 DNA ligase (400 U/µL; New England Biolabs Cat. No. M0202S). 
16. α-select Gold Efficiency E. Coli (≥109 cfu/μg; Bioline Cat. No. BIO-85027) 
17. Heated water bath. 
18. Humidified bacterial incubator. 
19. S.O.C. medium: 2% tryptone; 0.5% yeast extract; 10 mM NaCl; 2.5 mM KCl; 10 mM 
MgCl2; 10 mM MgSO4; and 20 mM glucose. Adjust to pH 7.0 and sterilize by passing 
through a 0.22 µm filter. 
20. Luria Bertani (LB) broth: 1 % tryptone; 0.5 % yeast extract; 171 mM NaCl. Adjust to pH 
7.0 and sterilize by autoclaving. 
21. Ampicillin: 100 mg/ml stock solution in dH2O, store at -20 ºC. 
22. LB-agar ampicillin bacterial culture petri dishes: dissolve 20 g of agar powder in 1 L of 
LB broth and mix well. Autoclave on a liquid cycle and let to cool until it is warm 
enough to touch (approximately 50 °C). Add ampicillin to a concentration of 100 µM and 
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swirl to mix (do not shake as this will create bubbles). Pour into petri dishes to 
completely cover the bottom surface. Allow the plates to set for 2 h at room temperature, 
and store sealed plates at 4 °C for up to 3 months. 
23. Bacterial culture orbital shaker. 
24. QIAprep Spin Miniprep Kit (50 prep; QIAGEN Cat. No. 27104). 
25. siKO_fw primer: 5’-CGAACGCTGACGTCATCAACC-3’ 
26. Glycerol for molecular biology (>99%). 
27. QIAfilter Plasmid Midi Kit (25 prep; QIAGEN Cat. No. 12243). 
 
2.2 Gene targeting 
1. Human pluripotent stem cells (in house or from various commercial suppliers). 
2. 100 mm tissue culture petri dishes. 
3. TeSR-E8 medium (500 mL kit; STEMCELL Technologies Cat. No. 05940). 
4. Vitronectin XF (250 µg/mL; STEMCELL Technologies Cat. No. 07180). 
5. UltraPure 0.5 M EDTA pH 8.0 (Life Technologies Cat. No. 15575020). 
6. Humidified tissue culture incubator with CO2 supply. 
7. Biosafety level 2 laminar air flow tissue culture hood. 
8. Y-27632 dihydrochloride (1 mg; Tocris Cat. No. 1254): to obtain a 10 mM solution 
dissolve 1 mg of Y-27632 powder into 312.25 µl of DMSO. Prepare single-use aliquots 
and store at -20 °C for up to 6 months. 
9. DPBS no calcium and no magnesium (500 mL; ThermoFisher Scientific Cat. No. 
14190250). 
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10. StemPro Accutase Cell Dissociation Reagent (100 mL; ThermoFisher Scientific Cat. No. 
A1110501). 
11. P3 Primary Cell 4D-Nucleofector X Kit L (12 reactions; Lonza Cat. No. V4XP-3012). 
12. Trypan blue: 0.4% solution in dH2O. 
13. Hemocytometer. 
14. pZFN_AAVS1-R-KKR plasmid (available from the corresponding authors). 
15. pZFN_AAVS1-L-ELD plasmid (available from the corresponding authors). 
16. pAAV-Neo_CAG-Cas9 plasmid (available from the corresponding authors). 
17. pAAV-Puro_siKO-sgRNA plasmid (custom, see Subheading 3.1 step 3.11). 
18. AAVS1-CAGGS-EGFP (Addgene #22212). 
19. 4D-Nucleofector Core Unit and X Unit (Lonza, Parts No. AAF-1002B and AAF-1002X) 
20. Puromycin dihydrochloride: 10 mg/ml stock solution in dH2O. Sterilize by passing 
through a 0.22 µm filter, and store at -20 °C for up to 1 year. 
21. Geneticin (G418 sulfate): 200 mg/ml stock solution in dH2O. Sterilize by passing 
through a 0.22 µm filter, and store at -20 °C for up to 1 year. 
 
2.2 Genotyping and validation 
1. 24 well tissue culture petri dishes. 
2. Penicillin-streptomycin: 10.000 U/ml solution. 
3. Wizard Genomic DNA Purification Kit (100 extractions; Promega Cat. No. A1120) 
4. LongAmp Taq DNA Polymerase (2.5 U/µL; New England Biolabs Cat. No. M0323S) 
5. dNTP mix: 10 mM dATP; 10 mM dCTP; 10 mM dGTP; 10 mM dTTP. 
6. Dimethyl sulfoxide (DMSO), PCR grade. 
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7. Genotyping primers (see Table 1 for full list and sequences): 5 µM stock solutions in 
dH2O. 
8. Tetracycline hydrochloride (cell-culture grade; Sigma-Aldrich Cat. No. T7660): to 
prepare a stock 10 mg/ml solution, dissolve 50 mg of tetracycline hydrochloride in 5 ml 
of dH2O. The resulting solution should have a mild yellow-orange color. Filter-sterilize 
using a 0.22 µm filter, and prepare single-use 5 or 10 µl aliquots. Store at -80 °C for up to 
6 months. Prepare and store this reagent protected from direct illumination. 
 
3 Methods 
Carry out all procedures at room temperature unless otherwise specified. 
 
3.1 Generation of inducible sgRNA targeting vector 
1. Identify a 20 bp sgRNA target sequence against the gene of interest by taking advantage 
of available sgRNA design tools (see Note 1). Testing of the candidate sgRNAs 
efficiency is optional but is strongly recommended (see Note 2). If the sgRNA sequence 
does not start with a guanine (“G”) or an adenosine (“A”), add a “G” to the 5’ end (see 
Note 3). 
2. Design the “top” oligonucleotide by adding 5’-TCCC-3’ to the 5’ end of the sgRNA 
target sequence (without PAM), and the “bottom” oligonucleotide by adding 5’-AAAC-
3’ to the 5’ end of the reverse complement of the sgRNA target sequence (without PAM). 
Annealing of these oligonucleotides will create a short double-strand DNA sequence with 
5’ overhangs suitable for subsequent directional cloning (Fig. 2c). Order both 
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oligonucleotides as desalted purified products from a preferred vendor, and resuspend at 
a concentration of 200 µM in dH2O. 
3. Prepare the backbone plasmid by digesting 5 µg of pAAV-Puro_siKO in a 100 µL 
reaction containing 5 µL (10 U) of AarI, 2 µL (0.5 µM) of the provided oligonucleotide, 
and 10 µL (1X) of the provided 10X AarI digestion buffer (remaining volume dH2O). 
Incubate at 37 ºC overnight (16 h; see Note 4). AarI is a type II restriction enzyme that 
cuts outside of its two recognition sites to create non-complementary 3’ overhangs 
suitable for seamless directional cloning of the sgRNA target sequence in front of the 
sgRNA scaffold (Fig. 2a-c). 
4. Add 20 µL (1X) of the 6X DNA gel loading dye, and perform standard DNA 
electrophoresis of the digestion product using a 1% agarose-TAE gel. Include a DNA 
ladder as molecular weight control. Visualize the DNA using a UV transilluminator, 
excise the 9551 bp band with a clean scalpel (see Note 5), and gel-extract the DNA using 
QIAEX II Gel Extraction Kit following the manufacturer’s instructions. Quantify the 
linearized plasmid, and adjust the concentration to 50 ng/µL. Keep on ice for same day 
use, or store in single-thaw aliquots at -20 °C for at least 6 months. 
5. Prepare the insert by annealing the top and bottom oligonucleotides from Subheading 3.1 
step 2 in a 20 µL reaction containing 5 µL (50 µM) of each oligo and 2 µL (1X) of 10X 
oligo annealing buffer (remaining volume dH2O). Incubate in a thermocycler for 5’ at 95 
°C, followed by slow descent to 4 °C by -0.1 °C/s, then dilute 1:500 in 1X oligo 
annealing buffer. Keep on ice for same day use (do not store). 
6. Assemble a 10 µL ligation reaction with 4 µL of the diluted annealed oligo, 1 µL (50 ng) 
of the linearized plasmid from Subheading 3.1 step 4, 1 µL (5 U) of T4 DNA Ligase, and 
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1 µL (1X) of the provided 10X T4 DNA Ligase Buffer (remaining volume dH2O). 
Incubate at room temperature for 2 h. 
 
[Fig. 2 near here] 
 
7. Transform 2 µL of the ligation product into 25 µL of α-select E. Coli according to 
manufacturer’s instructions using a heated water bath for heat-shock. Recover the 
transformed bacteria in 250 µL of S.O.C. media for 30’ at 37 °C, then plate all of the 
culture onto a LB-agar petri dish containing 100 µg/ml of ampicillin. Incubate overnight 
(16 h) at 37 °C in a humidified incubator. 
8. Pick individual bacterial colonies using a sterile tip and inoculate them into 4 ml of LB 
broth with 100 µg/ml of ampicillin (see Note 6). Incubate in a bacterial culture orbital 
shaker at 37 °C overnight (16 hours) while shaking at 225 rpm.  
9. Isolate plasmids from bacterial cultures using the QIAprep Spin Miniprep Kit following 
manufacturer’s instructions. Save 200 µl of each culture and store in the fridge. 
10. Confirm the presence of the desired sgRNA and the lack of mutations by performing 
Sanger DNA sequencing using the siKO_fw primer. Upon successful result, freshly 
inoculate the bacterial clone by diluting the previously saved liquid culture 1:1000 in 50 
mL of LB broth with 100 µg/ml of ampicillin. Incubate in a bacterial culture orbital 
shaker at 37 °C overnight (16 h) while shaking at 225 rpm. 
11. Prepare a glycerol stock to be stored at -80 °C for long-term backup by mixing 200 µl of 
sterile autoclaved 50% glycerol in dH2O with 200 µL of the bacterial culture. Isolate the 
plasmid from the remaining culture using the QIAfilter Midiprep Kit according to the 
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manufacturer’s instructions. Resuspend the resulting pAAV-Puro_siKO-sgRNA targeting 
vector in dH2O at a concentration of 1 µg/mL and store at -20 °C. 
 
3.2 Gene targeting of inducible CRISPR/Cas9 platform in hPSCs 
1. Grow hPSCs in mTeSR E8 medium and vitronectin-coated culture dishes according to 
the manufacturer’s instructions in a 37°C incubator with 5% CO2 and 95% humidity. 
Passage cells every 3 to 5 days using 0.5 mM EDTA to facilitate mechanical dissociation, 
and seed them as small clumps of 5-20 cells with sub-cultivation ratio of 1:3 to 1:10 (see 
Note 7). hPSCs to be used for nucleofection should be within their exponential growth 
phase (50-70% confluency; Fig. 3b), and 2x106 cells are required for each nucleofection. 
Positive and negative nucleofection controls are strongly recommended for first time 
users or when troubleshooting (see Note 8). Volumes are given for cells cultured in 100 
mm dishes. 
2. 16-24 h before nucleofection feed hPSCs with 10 mL of fresh TeSR-E8 media without 
antibiotics and supplemented with 10 µM Y-27632 (ROCK inhibitor; see Note 9).  
3. Before beginning the nucleofection procedure, prepare two vitronectin-coated 100 mm 
dishes for each nucleofection, aspirate the coating solution, add 10 mL of TeSR-E8 
medium supplemented with 10 µM Y-27632, and place in the 37°C incubator to pre-
warm and equilibrate. Thaw all the plasmids and adjust their concentration to 1 µg/ml. 
Add the supplement to the P3 nucleofection solution from the 4D-Nucleofector kit, and 
let acclimatize at room temperature. 
4. Begin cell collection by aspirating hPSC culture medium, rinsing the cells with 10 mL 
DPBS, and adding 5 ml of Accutase. Incubate for 3 to 5 min at 37 °C in the incubator 
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until colonies can be lifted by gently tapping on the side of the dish (Fig. 3c). Add 10 mL 
of TeSR-E8 medium, and mechanically triturate the colonies into clumps of 3-4 cells 
using a 5 mL serological pipette (Fig. 3d). 
5. Perform a live cell count using a hemocytometer after diluting an aliquot of the cells 1:2 
with trypan blue (see Note 10). Aliquot 2x106 live cells in a separate conical tube for each 
nucleofection, and pellet the cell suspension by spinning for 3’ at 115 g at room 
temperature. Remove the supernatant as completely as possible. 
6. Prepare the nucleofection mix in a sterile tube by adding 2 µL (2 µg) of pAAV-
Puro_siKO-sgRNA, 2 µL (2 µg) of pAAV-Neo_CAG-Cas9, 4 µL (4 µg) of 
pZFN_AAVS1-R-KKR, 4 µL (4 µg) of pZFN_AAVS1-L-ELD, and finally 100 µL of P3 
solution. Using a 1000 µL pipette tip transfer all of the mix to the tube containing the cell 
pellet, and resuspend the cells very gently by pipetting 3-5 times (see Note 11).  
7. Rapidly transfer the nucleofection mix to the provided nucleofection cuvette (see Note 
12), and pulse the cells by operating the program “CA-137” (see Note 13). Let the cells 
recover at room temperature for 5’. 
8. Add 500 µL of TeSR-E8 medium supplemented with 10 µM Y-27632 to the bottom of 
the cuvette, and using the provided suction pipette very gently transfer half of the cell 
suspension to each of the two pre-warmed 100 mm dishes from Subheading 3.2 step 3. 
Distribute drop by drop over the plate surface, and gently shake the plate back and forth 
then left and right 3-5 times to promote even plating. Incubate overnight in the 37 °C 
incubator (see Note 14). 
9. On the following day, visually confirm efficient cell attachment (Fig. 3e), and replace the 
culture media with fresh TeSR-E8 medium. Subsequently, perform daily media changes. 
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After 3 days from nucleofection, or when cells reach 50-70% confluence (Fig. 3f), begin 
dual drug selection by adding 0.5 µg/ml of puromycin and 25 µg/ml geneticin to the 
culture media (see Note 15). For the first 48 h of selection, further supplement the media 
with 10 µM Y-27632 (see Note 9). Selection should be complete within 48-72 h (Fig. 3g-
h; see Notes 8 and 16), after which the drugs can be withdrawn. Individual colonies 
should reach an appropriate size for passaging (1-2 mm; Fig. 3i) by 7-10 days after 
nucleofection (see Note 17). 
 
[Fig. 3 near here] 
 
3.3 Genotyping of OPTiKO hPSCs 
1. Mechanically pick an individual colony by using a micropipette equipped with a sterile 
tip. Use a microscope to facilitate visualization during the procedure. Transfer each 
colony to a single well of the 24 well tissue culture petri dish, then gently pipette 5-10 
times to triturate. Add penicillin-streptomycin to the culture media to minimize the risk of 
bacterial contamination, and further supplement it with 10 µM Y-27632 to promote hPSC 
survival. Repeat the procedure for 8-12 colonies (see Note 18). 
2.  Once they reach 50-70% confluency, split each clonal line into two wells of a 24-well 
plate: one with approximately 1/3 of the cells and the second with the remaining 2/3. 
Cells in the first well will be grown, while the second well will be used for genotyping. 
3. When the cells prepared for genotyping reach >50% confluency, extract genomic DNA 
using the Wizard Genomic DNA Purification Kit according to the manufacturer’s 
instructions. Adjust the DNA concentration to 25-50 ng/µL. 
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4. Individually assemble the genotyping polymerase chain reactions (PCR) detailed in Table 
1 using LongAmp Taq DNA Polymerase (see Note 19). For each reaction, prepare a 10 
µL mix containing: 100 ng of genomic DNA, 0.3 µL (300 µM) dNTP mix, 0.5 µL (250 
nM) forward primer, 0.5 µL (250 nM) reverse primer, 0.2 µL (2%) DMSO, and 0.4 µL 
(10 U) LongAmp Taq Polymerase (remaining volume dH2O). Inclusion of positive and 
negative controls is strongly recommended (see Note 20). 
5. Perform the PCR in a thermocycler according to the following program (lid heated at 95 
°C): (1) 94 °C for 5’; (2) 94 °C for 15’’; (3) annealing temperature (see Table 1) for 30’’; 
(4) 65 °C for extension time (see Table 1); (5) repeat steps 2 to 4 for a total of 35 cycles; 
(6) 65 °C for 3’; (7) hold at 10 °C. 
 
[Table 1 near here] 
 
6. Perform DNA gel electrophoresis for half of each PCR reaction with a 1% agarose-TAE 
gel, and visualize the results with a UV transilluminator (see Subheading 3.1 step 4; Fig. 
4b). 
7. Determine the genotype of OPTiKO clones by referring to Table 2 (see Note 19). Only 
clones showing dual targeting of both the Cas9 and sgRNA transgenes are OPTiKO 
hPSCs that should be kept for further experiments. 
8. Identify the clones of interest from the second 24 well plate from Subheading 3.3 step 1. 
Once they are ready to be passaged split them for expansion, banking, and experimental 
analyses. 
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[Fig. 4 near here] 
 
[Table 2 near here] 
 
3.4 Validation of OPTiKO hPSCs 
1. Knockout can be induced in hPSCs or hPSC-derived cells by adding the drug tetracycline 
to the culture media at a concentration of 1 µg/ml (see Notes 21 and 22). The duration of 
tetracycline treatment required to induce knockout in the majority of the cells will depend 
on the efficiency of the sgRNA and on the cell type (Fig. 5), but ought to be in the range 
of 2-10 days (see Note 23). 
2. Validation of gene knockout should be performed by means of appropriate techniques 
described in detail elsewhere (see Notes 24 and 25). The quantification of 
CRISPR/Cas9-induced indels on the genomic locus can be efficiently assessed using the 
Surveyor or T7 endonuclease 1 assay (Fig. 5a), by DNA Sanger sequencing, and/or by 
next-generation sequencing [17, 25] (see Note 26). Mutations introducing premature stop 
codons will often result in decreased transcript levels due to nonsense-mediated decay, 
which can be easily measured by quantitative reverse transcription PCR (RT-qPCR) [26]. 
Finally and most importantly, loss of the protein product can be validated by flow 
cytometry (Fig. 5b), immunocytochemistry (Fig. 5c-e), and/or Western blot [16, 27–30] 
(see Note 27). 
3. Validated OPTiKD hPSCs may now be used to investigate the biological question of 
interest (Fig. 5f; see Note 28). 
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[Fig. 5 near here] 
 
4 Notes 
 
1 sgRNA design should consider several aspects including the cut site location (conserved 
and constitutive exons located towards the start of the coding sequence and/or encoding 
for crucial protein domains are to be preferred), and the predicted activity and specificity 
of the sgRNA [31, 32]. Publicly available resources for sgRNA design are numerous and 
reviewed elsewhere [33]. We recommend the online tools CRISPR design 
(http://crispr.mit.edu) or GuideScan [34], or the standalone software Protospacer 
Workbench [35]. 
2 Even more so than for conventional CRISPR/Cas9 applications, identification of an 
efficient sgRNA is the most critical factor in the success of OPTiKO experiments [16, 
17]. The sgRNA will be expressed from a single transgenic copy, and will therefore be in 
limiting amounts. As a result, efficient gene editing will be achieved only with a sgRNA 
highly effective in inducing double-strand DNA breaks (see Note 23). It is therefore 
highly recommended to pre-screen 3 to 5 sgRNAs using an appropriate method, such as 
the inexpensive T7 endonuclease I (T7EI) assay [36], and to select the sgRNA showing 
the highest activity. 
3 Distinctly from the U6 promoter (which prefers transcription of sgRNAs starting with 
guanine), either a guanine or an adenosine may support efficient and precise transcription 
from the H1 Pol III promoter [37, 38]. Addition of a guanine at the start of sgRNAs not 
satisfying this criterion does not substantially influence gene editing efficiency. 
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4 AarI requires binding to two copies of its recognition sequence for cleavage (the second 
copy is provided by the oligonucleotide to be included in the digestion reaction), and is a 
slow cutter that requires extended incubation for complete plasmid digestion. 
5 Occasional AarI star activity after overnight digestion can lead to the presence non-
specific products smaller in size compared to the expected linearized plasmid. Provided 
that the linearized plasmid is the predominant digestion product and it can be clearly 
identified and distinguished after an appropriate electrophoretic run, this will not interfere 
with the efficiency of subsequent ligation. If this is not the case, however, the digestion 
time should be shortened to 4-8 h. 
6 We recommend screening 4 to 8 bacterial clones. If the procedure was successful, the 
expected recombinant DNA should be found it more than 90% of the clones. Should the 
efficiency prove significantly lower, colony PCR can be used as a rapid method to screen 
several clones [16]. For this, use the siKO_fw primer and the bottom sgRNA 
oligonucleotide as reverse primer in order to detect an approximately 250 bp product in 
the clones carrying the sgRNA. Additionally, correct recombinant clones can be screened 
by diagnostic digestion with AarI, as this will be unable to digest the desired recombinant 
DNA (provided no AarI site is found within the sgRNA sequence). 
7 The culture conditions recommended in this protocol rely on commercially available and 
commonly used reagents for feeder- and xeno-free hPSC culture. Nevertheless, OPTiKO 
hPSCs have been successfully derived from cells maintained in various culture conditions 
including gelatin-fibronectin coating with an in house chemically defined media, matrigel 
coating with mTeSR1, and laminin-521 coating with E8 [16, 17]. 
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8 A positive control can be performed by using an AAVS1 targeting vector expressing a 
constitutive EGFP transgene (AAV-CAGGS-EGFP) instead of the OPTiKO plasmids. 
Cells can be visually monitored for EGFP expression the day following nucleofection to 
confirm efficient plasmid delivery, and the nucleofected cells can be subjected to drug 
selection to confirm efficient gene targeting of the AAVS1 locus (see Subheading 3.2 step 
9). Note that this targeting vector confers resistance only to puromycin, so geneticin 
should be omitted. A negative control nucleofection without any plasmid can be 
performed to monitor the efficiency of drug selection: the nucleofected cells should be 
completely killed within 48-72 h of drug selection. Finally, an additional negative control 
nucleofection only with the OPTiKO plasmids but omitting the AAVS1 zinc finger 
nucleases can be performed to confirm the low rate of transgene integration outside of the 
AAVS1 locus: no or very few colonies should survive drug selection. 
9 The use of antibiotics is optional at all other stages of the procedure but must be avoided 
the day before and the day after the nucleofection, as they are toxic in cells with 
increased cell membrane permeability. The addition of ROCK inhibitor before and after 
nucleofection increases hPSC survival by inhibiting apoptosis [39]. 
10 Viability should be greater than 90%. If this is significantly lower, increase the duration 
of Accutase treatment up to 7’ to reduce the amount of mechanical trituration to the 
minimum required to obtain 3-4 cell clumps.  
11 Use of a pipette tip with a large orifice is key to limit shear stress on nucleofected cells. 
Pipetting should be very gentle and minimized as much as possible. In particular, cells 
post-nucleofection are incredibly fragile and should be mixed only a couple of times, 
preferably using a large bore pipette tip. 
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12 Ensure that no air bubbles are trapped at the bottom of the cuvette. If so, a sharp tap 
should be sufficient to dislodge them. 
13 The combination of the recommended nucleofection solution and nucleofection program 
has been optimized for H9 hESCs, and proved to work efficiently also in hiPSCs (40-
60% nucleofection efficiency). Nevertheless, this might require some degree of 
optimization for certain hPSC lines. Consult the nucleofector manufacturer’s instructions 
for alternative nucleofection solutions and programs suitable for hPSCs. 
14 An alternative to the recommended feeder-free procedure is plating the nucleofected cells 
onto feeder layers of mitotically inactivated MEF cells [16]. While more expensive, 
laborious, and not xenofree, this approach may increase gene editing efficiency of certain 
hPSC lines due to improved survival both after nucleofection and during drug selection. 
In this case, utilize DR4 MEF (Applied StemCell) that are genetically engineered to 
contain resistance to puromycin and neomycin, and top up the feeder layer as needed 
during drug selection (some cell death of the MEF feeder will be observed despite their 
drug resistance). 
15 The recommended drug doses have been optimized for H9 hESCs, and proved to work 
efficiently also for hiPSCs. Nevertheless, based on the results of the positive and negative 
controls described in Note 8, optimization might be required for certain hPSC lines. In 
this case, perform a kill curve experiment to identify the minimal dose required to 
completely select wild-type hPSCs within 48-72 h of drug selection (range: 0.25-2 µg/ml 
of puromycin and 12.5-200 µg/ml geneticin). 
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16 During the first 48 h of selection it can be beneficial to increase the media volume to 20 
mL and to perform media changes every 12 h in order to rapidly remove dead cells, thus 
reducing the stress they impose on the surviving hPSCs. 
17 5-50 individual hPSC colonies should be obtained in each of the two 100 mm dish. An 
individual colony is expected to result from clonal expansion of a single cell that 
experienced the rare gene editing event in which both AAVS1 alleles have been targeted 
with the two different transgenes. Therefore, provided that such a pseudo-clonal colony is 
not in close proximity to any other, this will be considered and referred to as “clonal”. 
Should a more stringent way to generate clonal lines be desirable, hPSCs should be 
plated as single cells into 96 or 384well plates and grown as bona fide clones. 
18 Given the high efficiency of the gene targeting procedure, the proportion of correctly 
targeted hPSCs is expected to be greater than 90% [16]. As a matter of fact, while clonal 
isolation is recommended in order to obtain an isogenic population, this may be entirely 
bypassed in experimental situations where this is not an important requirement (such as 
for analyses that will be performed at the single cell level). In such case, simply passage 
the whole 100 mm dishes into new plates and proceed to validation (Subheading 3.4). 
19 The recommended genotyping strategies are illustrated in Fig. 4a. The 5’- and 3’-
intergration (INT) PCRs are designed to verify site-specific integration of the transgenes. 
Targeting of both alleles of the AAVS1 locus is further confirmed by loss-of-allele PCR 
for the wild type locus (this PCR fails following successful transgene integration due to 
the large size of the amplicon and the high GC content of the CAG promoter). Finally, 5’- 
and 3’-backbone (BB) PCRs allow to determine if the targeting plasmids have been 
integrated in a random genomic region. Note that the BB PCRs are optional, as the 
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presence of additional transgenic copies does not interfere with the functionality of the 
method. Nevertheless, selection of clones with exactly one copy of each transgene can be 
advantageous in certain experimental settings, for instance when comparing the 
efficiency of different sgRNAs [17]. 
20 Recommended controls are: wild-type genomic DNA, 100 ng; pAAV-Neo_CAG-Cas9 
(Cas9 targeting plasmid), 1 ng; pAAV-Puro_siKO-sgRNA (sgRNA targeting plasmid), 1 
ng; and no template control, dH2O (Fig. 4b). 
21 This dose of tetracycline is not toxic to hPSCs and does not interfere with hPSC 
differentiation into multiple lineages from all the germ layers [16]. Nevertheless, this 
might require optimization for a specific sensitive cell type (range: 0.05-2 µg/ml). 
Tetracycline is unstable in aqueous solutions, and should be added fresh from single-use 
freshly-thawed aliquots (see Materials). Media changes should be performed at least 
every other day since the half-life of tetracycline at 37 °C is of approximately 24 h.  
22 Given the widespread use of tetracycline as an antibiotic in livestock animals, animal-
derived products such as fetal bovine serum (FBS) may be contaminated with 
tetracycline. When such reagents have to be included as part of the culture media to be 
used for hPSC maintenance or differentiation, batch testing to confirm lack of detectable 
tetracycline contamination is strongly recommended. Tetracycline-free FBS is available 
from commercial suppliers. 
23 As introduced in Note 2, the speed and efficiency of knockout will be predominantly 
dictated by the activity of the sgRNA. Should the performance of a given sgRNA be 
insufficient to appropriately investigate the biological question at hand, an alternative is 
to build a pAAV-Puro_siKO plasmid containing multiple copies of the sgRNA. This can 
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be achieved by a one-step Gibson assembly reaction using PCR-amplified inducible 
sgRNA expression cassettes [16]. Of note, this method can also be applied to express 
multiple distinct sgRNAs against the same gene, or multiple sgRNAs against different 
genes.  
24 For most sgRNAs the level of gene knockout in absence of the inducer tetracycline 
should be minimal (less than 5%) even after prolonged passaging [16, 17]. However, rare 
exceptionally potent sgRNAs can induce even substantial premature gene knockout. In 
such case, it is recommended to repeat the procedure using an alternative targeting vector 
for sgRNA cloning: pAAV-Puro_siKO-2TO (available from the corresponding authors). 
In such plasmid the inducible H1 promoter has an additional tetO2 binding side for the 
tetR before the TATA box, thus reinforcing transcriptional repression in the absence of 
tetracycline [16, 40]. Note that this modification also results in lower sgRNA expression 
levels after addition of tetracycline, thus making it a valuable option only in case of 
exceptionally strong sgRNAs. 
25 The kinetics by which acquisition of knockout mutations leads to loss of the protein 
product is heavily dependent on the stability of both the mRNA and the protein. 
Furthermore, decrease in protein levels will be more marked in dividing cells (which will 
serially dilute the protein after each cell cycle) compared to non-proliferative cells. 
Therefore, the timing required for efficient knockout ought to be determined for each 
gene and cell type to be studied. 
26 The same methods should also be applied to determine the degree of possible 
CRISPR/Cas9 off-targets effects based on in silico predictions. Indeed, while these ought 
to be minimized by careful design of the sgRNA (see Note 1), the method relies on wild 
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type Streptococcus Pyogenes Cas9 protein, which is known to suffer from some degree of 
off-target activity [41, 42]. 
27 The OPTiKO method can be also applied to introduce indels in non-coding regions of the 
genome, which represent an important proportion of disease-associated sequences [1, 2]. 
In this case, validation will primarily focus on determining the mutations at the DNA 
level. 
28 Analysis of OPTiKO cells maintained in parallel and cultured in absence of tetracycline 
must be always implemented to provide a reference for the experiment. Additionally, 
when investigating a new cell type and/or biological process we recommend to also 
analyze cells treated with tetracycline but lacking the specific inducible sgRNA, in order 
to control for potential non-specific effects due to the drug [43, 44]. For this, OPTiKO 
cells carrying a scrambled sgRNA are the ideal control, as they also allow to monitor for 
potential non-specific effects of CRISPR/Cas9 expression. Alternatively, use wild-type 
cells, or cells expressing the Cas9 transgene. Since clonal isolation of hPSCs can 
exacerbate biological variability, it is important to analyze multiple OPTiKO clones for 
the same sgRNA to ensure that the results are reproducible. Finally, analysis of OPTiKO 
cells carrying separate sgRNAs designed to target the same gene will reinforce the 
conclusion of any experimental analysis by ruling out the possibility that the observed 
phenotypes are due to unappreciated off-targets of the sgRNA. 
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Figure Captions 
Figure 1. The optimized inducible knockout (OPTiKO) system. 
Schematic of the generation of OPTiKO human pluripotent stem cells (hPSCs) and of the resulting 
genetic circuit which allows tetracycline (TET)-dependent induction of gene knockout both in 
hPSCs and hPSC-derived cells. 
 
Figure 2. Cloning of sgRNAs into the OPTiKO plasmid 
(A) Map of the AAVS1 targeting vector carrying the inducible sgRNA: the transgene is integrated 
following homologous directed repair (HDR), and employs a gene-trap approach to drive the drug 
resistance gene through the endogenous promoter of the AAVS1 locus (Fig. 4). HA-L/R: left/right 
homology arms; SA: splice acceptor; T2A: self-splicing T2A sequence; PuroR: puromycin 
resistance cDNA; pA: polyadenylation sequence; H1-TO: tetracycline-inducible H1 RNA 
Polymerase III promoter containing a tetO2 sequence; CAG: CMV early enhancer, chicken β-
actin, and rabbit β-globin hybrid constitutive promoter; OPTtetR: codon-opimized tetracycline-
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responsive repressor protein cDNA; AmpR: ampicillin resistance; ori: high-copy origin of 
replication. (B) Nucleotide sequence of the tetracycline-inducible H1-TO RNA Polymerase III 
promoter. Key features are color coded. The restriction enzyme sites used for sgRNA cloning are 
shown in boxes (panel C). DSE: distal sequence element; PSE: proximal sequence element; 
TETO2: tet operator; +1: start position of RNA transcription; Pol III term: poly(T) sequence 
inducing transcription termination. (C) Schematics of the sgRNA cloning procedure described in 
Subheading 3.1. 
 
Figure 3. Generation of OPTiKO hPSCs by gene targeting. 
(A) Schematic of the gene targeting procedure described in Subheading 3.2. The resulting OPTiKO 
transgenic alleles and their functionality in presence or absence of tetracycline (TET) are shown. 
ZFN: zinc finger nuclease; i-sgRNA: inducible sgRNA; iKO: inducible knockout; KO: knockout. 
(B-I) Representative phase-contrast images of hPSCs at the indicated stages of the gene targeting 
procedure. Scale bars: 250 μM. 
 
Figure 4. Genotyping of OPTiKO hPSCs. 
(A) Schematic of the AAVS1 gene targeting event that generates the OPTiKO transgenic alleles 
through homologous recombination of the donor plasmids (features are not in scale). AAV prom: 
endogenous promoter of the AAVS1 locus (PPP1R12C gene), which drives the gene-trap drug 
resistance genes. The genotyping strategies used to identify correctly targeted hPSCs are shown 
(Subheading 3.3). Locus PCR: PCR product of wild-type AAVS1 locus (indicating a non-targeted 
allele); Loss-of-allele: potential PCR amplification that fails onto the targeted allele due to large 
size and high GC-content; 5’/3’-INT PCR: PCR product of transgene 5’/3’-end integration region 
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(indicative of expected transgene targeting); 5’/3’-BB PCR: PCR product of vector backbone 
5’/3’-end (indicative of non-specific off-target plasmid integration). (B) Representative example 
of genotyping results from 4 OPTiKO clonal sublines. For all clones the AAVS1 locus is correctly 
targeted with both transgenes, while clones 3 and 4 also carry randomly integrated copies of the 
targeting plasmid (Table 2). All clones could be used for further experiments. The predicted size 
of each PCR amplicon is indicated (Table 1), and a molecular weight control is shown on the left. 
WT: control PCR from wild-type hPSCs; sgRNA: control PCR from pAAV-Puro_siKO plasmid; 
Cas9: control PCR from pAAV-Neo_CAG-Cas9 plasmid; H2O: no template control. 
 
Figure 5. Performance of OPTiKO in hPSCs and hPSC-derived cells. 
(A) T7 endonuclease 1 (T7E1) assay in EGFPd2 OPTiKO hESCs [16]. hESCs constitutively 
expressing a destabilized EGFP transgene (homozygous ROSA26 CAG-EGFPd2 hESCs) were re-
targeted with the OPTiKO plasmids to drive an inducible sgRNA against EGFP. Cells were 
analyzed in absence (CTR) or presence of tetracycline (TET) for 24 h. A 1.47 Kb fragment around 
the sgRNA cut site was amplified by PCR and analyzed by T7E1 assay. The presence of indels in 
tetracycline-treated cells led to T7E1-mediated cleavage of the genomic fragment into the 
indicated products (MUT-1 and MUT-2). (B) Quantification of EGFPd2 by flow cytometry in 
EGFPd2 OPTiKO hESCs. >95% knockout could be achieved following 72 h of induction. (C-E) 
Analysis by immunocytochemistry of EGFP2d OPTiKO hESCs (C), hESC-derived neurons (D), 
and hESC-derived cardiomyocytes (E). EGFPd2 fluorescence is shown in green, while for D and 
E lineage-specific markers are shown in red. DAPI: nuclear staining. Scale bars: 100 μM. 
Widespread loss of EGFPd2 expression could be achieved in all lineages. (F) Analysis by flow 
cytometry of OCT4 OPTiKO hESCs [17]. Cells were analyzed for expression of OCT4 and of the 
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endoderm marker SOX17. The result demonstrate that loss of OCT4 expression led to endoderm 
differentiation in a subpopulation of hESCs.  
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Tables 
Table 1 – Primers for genotyping of OPTiKO clonal lines 
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1 Result of PCR on wild-type AAVS1 allele 
2 Result of PCR on OPTiKO-targeted AAVS1 allele 
3 Result of PCR on targeting vector (positive control for off-target plasmid integration) 
4 Variable parameter in PCR protocol (Subheading 3.3 step 5) 
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Table 2 – Inferring the genotype of OPTiKO clonal lines from PCR results. 
 
5’- and 3’-INT sgRNA 5’- and 3’-INT Cas9 Locus 5’- and 3’-BB (any) Possible Genotype1 
Both bands at expected 
size 
Both bands at expected 
size 
No band No bands Dual targeting of both 
sgRNA and Cas9 
Both bands of expected 
size 
Both bands of expected 
size 
No band At least one band at 
expected size 
Dual targeting of both 
sgRNA and Cas9, with 
additional sgRNA/Cas9 
plasmid copies2 
Both bands at expected 
size 
One or more band absent 
or at incorrect size 
Band at expected size Any Targeting of sgRNA 
only 
One or more band absent 
or at incorrect size 
Both bands at expected 
size 
Band at expected size Any Targeting of Cas9 only 
Both bands at expected 
size 
Both bands of expected 
size 
Band at expected size Any Population is likely not 
clonal. 
No bands No bands Band at expected size At least one band at 
expected size 
Random transgene 
integration 
 
1 Only the most common results are described. Refer to Note 19 and Fig. 4 to interpret other possible genotyping results. 
2 Alternatively the targeting plasmid is still present in the cells as an episome. 
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